{"id":8012,"date":"2023-12-05T12:44:15","date_gmt":"2023-12-05T12:44:15","guid":{"rendered":"https:\/\/dailyai.com\/?p=8012"},"modified":"2023-12-05T12:48:06","modified_gmt":"2023-12-05T12:48:06","slug":"astrazeneca-bets-247m-on-ai-company-developing-cancer-drug","status":"publish","type":"post","link":"https:\/\/dailyai.com\/pt\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","title":{"rendered":"AstraZeneca aposta $247 milh\u00f5es numa empresa de IA que desenvolve um medicamento contra o cancro"},"content":{"rendered":"<p><strong>A AstraZeneca comprometeu-se a investir $247 milh\u00f5es para financiar os esfor\u00e7os da Absci, uma empresa de descoberta de medicamentos com IA, para desenvolver um anticorpo contra o cancro.<\/strong><\/p>\n<p>A Absci utiliza a sua fun\u00e7\u00e3o generativa <a href=\"https:\/\/dailyai.com\/pt\/2023\/07\/ai-accelerates-discovery-of-anti-aging-drugs-in-new-study\/\">Descoberta de medicamentos com IA<\/a> para descobrir potenciais novos medicamentos e depois valida-os nos seus laborat\u00f3rios h\u00famidos.<\/p>\n<p>Com o projeto apoiado pela AstraZeneca, a Absci tentar\u00e1 criar um anticorpo que se ligue a um alvo oncol\u00f3gico espec\u00edfico. A empresa ainda n\u00e3o revelou qual o tipo de cancro que pretende atingir com este projeto.<\/p>\n<p>Os anticorpos s\u00e3o uma perspetiva atractiva para <a href=\"https:\/\/dailyai.com\/pt\/2023\/06\/researchers-build-breakthrough-ai-model-for-drug-discovery\/\">novos medicamentos<\/a> porque s\u00e3o altamente selectivos nos alvos a que se ligam e resultam em efeitos imunog\u00e9nicos m\u00ednimos. No entanto, \u00e9 dif\u00edcil encontrar um novo anticorpo facilmente fabric\u00e1vel com propriedades espec\u00edficas.<\/p>\n<p>O n\u00famero de combina\u00e7\u00f5es poss\u00edveis de prote\u00ednas para criar diferentes anticorpos \u00e9 praticamente ilimitado. Por isso, encontrar um que fa\u00e7a o que se pretende envolve alguma adivinha\u00e7\u00e3o educada e tentativa e erro.<\/p>\n<p>Este facto faz com que a descoberta tradicional de anticorpos exija muito tempo e recursos. Envolve o rastreio de grandes bibliotecas imunes ou sint\u00e9ticas para encontrar potenciais candidatos a anticorpos. Estes candidatos t\u00eam depois de ser sintetizados antes de se confirmar se se ligam de forma \u00f3ptima ao alvo.<\/p>\n<p>A plataforma de Cria\u00e7\u00e3o Integrada de Medicamentos da Absci utiliza modelos de aprendizagem autom\u00e1tica treinados em ensaios de laborat\u00f3rio h\u00famido, ou procedimentos experimentais, gerando milhares de milh\u00f5es de dados de intera\u00e7\u00e3o prote\u00edna-prote\u00edna.<\/p>\n<p>O modelo de IA aprende os princ\u00edpios de engenharia subjacentes que fazem com que as diferentes prote\u00ednas se comportem da forma como o fazem. A plataforma utiliza o seu motor de IA generativo para criar anticorpos sint\u00e9ticos de novo, ou a partir do zero, numa abordagem de tiro zero.<\/p>\n<p>No caso dos anticorpos, uma abordagem de tiro zero significa que as prote\u00ednas candidatas que a IA gera se baseiam nos primeiros princ\u00edpios, em vez de se basearem em dados hist\u00f3ricos de outras prote\u00ednas conhecidas por se ligarem a um agente patog\u00e9nico espec\u00edfico.<\/p>\n<p>A utiliza\u00e7\u00e3o da IA permite \"adivinhar\" muito mais rapidamente e com maior exatid\u00e3o quais as prote\u00ednas que podem valer a pena investigar do que a abordagem humana de acerto e erro.<\/p>\n<p>As prote\u00ednas candidatas s\u00e3o depois validadas experimentalmente nos laborat\u00f3rios h\u00famidos da Absci. A plataforma de design de prote\u00ednas com IA acelera a descoberta de medicamentos ao concluir o ciclo de recolha de dados, design orientado por IA e valida\u00e7\u00e3o em laborat\u00f3rio h\u00famido em cerca de seis semanas.<\/p>\n<p>Falando sobre a sua parceria com a AstraZeneca, o CEO da Absci, Sean McClain, afirmou: \"A AstraZeneca \u00e9 l\u00edder no desenvolvimento de novos tratamentos em oncologia e estamos entusiasmados por colaborar com eles na conce\u00e7\u00e3o de um candidato a anticorpo terap\u00eautico com potencial para melhorar a vida dos doentes com cancro\"<\/p>\n<p>O compromisso financeiro da AstraZeneca para com o projeto \u00e9 um sinal promissor de que a empresa est\u00e1 otimista quanto ao seu potencial de sucesso. Utilizar a IA para acelerar o desenvolvimento de <a href=\"https:\/\/dailyai.com\/pt\/2023\/08\/ai-powered-blood-test-detects-cancers-in-single-dna-molecules\/\">cancro<\/a> Os medicamentos ter\u00e3o um grande impacto na vida dos doentes, bem como nas finan\u00e7as das grandes empresas farmac\u00eauticas.<\/p>","protected":false},"excerpt":{"rendered":"<p>A AstraZeneca comprometeu-se a investir $247 milh\u00f5es para financiar os esfor\u00e7os da Absci, empresa de IA para a descoberta de medicamentos, no desenvolvimento de um anticorpo contra o cancro. A Absci utiliza a sua plataforma generativa de descoberta de medicamentos com IA para descobrir potenciais novos medicamentos e depois valida-os nos seus laborat\u00f3rios h\u00famidos. Com o projeto apoiado pela AstraZeneca, a Absci tentar\u00e1 criar um anticorpo que se ligue a um alvo oncol\u00f3gico espec\u00edfico. A empresa ainda n\u00e3o revelou qual o tipo de cancro que pretende atingir com este projeto. Os anticorpos s\u00e3o uma perspetiva atraente para novos medicamentos porque s\u00e3o altamente selectivos nos alvos a que se ligam e resultam em efeitos imunog\u00e9nicos m\u00ednimos. No entanto, encontrar um<\/p>","protected":false},"author":6,"featured_media":8014,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[84],"tags":[150,203,107],"class_list":["post-8012","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry","tag-ai-benefits","tag-biotech","tag-generative-ai"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AstraZeneca bets $247m on AI company developing cancer drug | DailyAI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dailyai.com\/pt\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca has committed $247 million to fund AI drug discovery company Absci\u2019s efforts to develop an antibody for cancer. Absci uses its generative AI drug discovery platform to discover potential new drugs and then validates these in its wet-labs. With the AstraZeneca-backed project, Absci will try to create an antibody that binds to a specific oncology target. The company hasn\u2019t yet revealed which type of cancer it is targeting with this project. Antibodies are an attractive prospect for new drugs because they are highly selective in the targets they bind to and result in minimal immunogenic effects. However, finding an\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dailyai.com\/pt\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"DailyAI\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-05T12:44:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-05T12:48:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"501\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Eugene van der Watt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DailyAIOfficial\" \/>\n<meta name=\"twitter:site\" content=\"@DailyAIOfficial\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Eugene van der Watt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"},\"author\":{\"name\":\"Eugene van der Watt\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/person\\\/7ce525c6d0c79838b7cc7cde96993cfa\"},\"headline\":\"AstraZeneca bets $247m on AI company developing cancer drug\",\"datePublished\":\"2023-12-05T12:44:15+00:00\",\"dateModified\":\"2023-12-05T12:48:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"},\"wordCount\":434,\"publisher\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"keywords\":[\"AI benefits\",\"Biotech\",\"Generative AI\"],\"articleSection\":[\"Industry\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\",\"url\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\",\"name\":\"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"datePublished\":\"2023-12-05T12:44:15+00:00\",\"dateModified\":\"2023-12-05T12:48:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"width\":1000,\"height\":501},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/dailyai.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca bets $247m on AI company developing cancer drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#website\",\"url\":\"https:\\\/\\\/dailyai.com\\\/\",\"name\":\"DailyAI\",\"description\":\"Your Daily Dose of AI News\",\"publisher\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dailyai.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\",\"name\":\"DailyAI\",\"url\":\"https:\\\/\\\/dailyai.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Daily-Ai_TL_colour.png\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Daily-Ai_TL_colour.png\",\"width\":4501,\"height\":934,\"caption\":\"DailyAI\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/DailyAIOfficial\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/dailyaiofficial\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@DailyAIOfficial\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/person\\\/7ce525c6d0c79838b7cc7cde96993cfa\",\"name\":\"Eugene van der Watt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"caption\":\"Eugene van der Watt\"},\"description\":\"Eugene comes from an electronic engineering background and loves all things tech. When he takes a break from consuming AI news you'll find him at the snooker table.\",\"sameAs\":[\"www.linkedin.com\\\/in\\\/eugene-van-der-watt-16828119\"],\"url\":\"https:\\\/\\\/dailyai.com\\\/pt\\\/author\\\/eugene\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca aposta $247m em empresa de IA que desenvolve medicamento contra o cancro | DailyAI","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dailyai.com\/pt\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","og_locale":"pt_PT","og_type":"article","og_title":"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI","og_description":"AstraZeneca has committed $247 million to fund AI drug discovery company Absci\u2019s efforts to develop an antibody for cancer. Absci uses its generative AI drug discovery platform to discover potential new drugs and then validates these in its wet-labs. With the AstraZeneca-backed project, Absci will try to create an antibody that binds to a specific oncology target. The company hasn\u2019t yet revealed which type of cancer it is targeting with this project. Antibodies are an attractive prospect for new drugs because they are highly selective in the targets they bind to and result in minimal immunogenic effects. However, finding an","og_url":"https:\/\/dailyai.com\/pt\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","og_site_name":"DailyAI","article_published_time":"2023-12-05T12:44:15+00:00","article_modified_time":"2023-12-05T12:48:06+00:00","og_image":[{"width":1000,"height":501,"url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","type":"image\/jpeg"}],"author":"Eugene van der Watt","twitter_card":"summary_large_image","twitter_creator":"@DailyAIOfficial","twitter_site":"@DailyAIOfficial","twitter_misc":{"Escrito por":"Eugene van der Watt","Tempo estimado de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#article","isPartOf":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"},"author":{"name":"Eugene van der Watt","@id":"https:\/\/dailyai.com\/#\/schema\/person\/7ce525c6d0c79838b7cc7cde96993cfa"},"headline":"AstraZeneca bets $247m on AI company developing cancer drug","datePublished":"2023-12-05T12:44:15+00:00","dateModified":"2023-12-05T12:48:06+00:00","mainEntityOfPage":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"},"wordCount":434,"publisher":{"@id":"https:\/\/dailyai.com\/#organization"},"image":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","keywords":["AI benefits","Biotech","Generative AI"],"articleSection":["Industry"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","url":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","name":"AstraZeneca aposta $247m em empresa de IA que desenvolve medicamento contra o cancro | DailyAI","isPartOf":{"@id":"https:\/\/dailyai.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"image":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","datePublished":"2023-12-05T12:44:15+00:00","dateModified":"2023-12-05T12:48:06+00:00","breadcrumb":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"]}]},{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","width":1000,"height":501},{"@type":"BreadcrumbList","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dailyai.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca bets $247m on AI company developing cancer drug"}]},{"@type":"WebSite","@id":"https:\/\/dailyai.com\/#website","url":"https:\/\/dailyai.com\/","name":"DailyAI","description":"A sua dose di\u00e1ria de not\u00edcias sobre IA","publisher":{"@id":"https:\/\/dailyai.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dailyai.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Organization","@id":"https:\/\/dailyai.com\/#organization","name":"DailyAI","url":"https:\/\/dailyai.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/dailyai.com\/#\/schema\/logo\/image\/","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/06\/Daily-Ai_TL_colour.png","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/06\/Daily-Ai_TL_colour.png","width":4501,"height":934,"caption":"DailyAI"},"image":{"@id":"https:\/\/dailyai.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/DailyAIOfficial","https:\/\/www.linkedin.com\/company\/dailyaiofficial\/","https:\/\/www.youtube.com\/@DailyAIOfficial"]},{"@type":"Person","@id":"https:\/\/dailyai.com\/#\/schema\/person\/7ce525c6d0c79838b7cc7cde96993cfa","name":"Eugene van der Watt","image":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","caption":"Eugene van der Watt"},"description":"Eugene vem de uma forma\u00e7\u00e3o em engenharia eletr\u00f3nica e adora tudo o que \u00e9 tecnologia. Quando faz uma pausa no consumo de not\u00edcias sobre IA, pode encontr\u00e1-lo \u00e0 mesa de snooker.","sameAs":["www.linkedin.com\/in\/eugene-van-der-watt-16828119"],"url":"https:\/\/dailyai.com\/pt\/author\/eugene\/"}]}},"_links":{"self":[{"href":"https:\/\/dailyai.com\/pt\/wp-json\/wp\/v2\/posts\/8012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailyai.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailyai.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailyai.com\/pt\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/dailyai.com\/pt\/wp-json\/wp\/v2\/comments?post=8012"}],"version-history":[{"count":5,"href":"https:\/\/dailyai.com\/pt\/wp-json\/wp\/v2\/posts\/8012\/revisions"}],"predecessor-version":[{"id":8018,"href":"https:\/\/dailyai.com\/pt\/wp-json\/wp\/v2\/posts\/8012\/revisions\/8018"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailyai.com\/pt\/wp-json\/wp\/v2\/media\/8014"}],"wp:attachment":[{"href":"https:\/\/dailyai.com\/pt\/wp-json\/wp\/v2\/media?parent=8012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailyai.com\/pt\/wp-json\/wp\/v2\/categories?post=8012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailyai.com\/pt\/wp-json\/wp\/v2\/tags?post=8012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}